VEGF signaling: Role in angiogenesis and beyond
- PMID: 38280470
- DOI: 10.1016/j.bbcan.2024.189079
VEGF signaling: Role in angiogenesis and beyond
Abstract
Angiogenesis is a crucial process for tissue development, repair, and tumor survival. Vascular endothelial growth factor (VEGF) is a key driver secreted by cancer cells, promoting neovascularization. While VEGF's role in angiogenesis is well-documented, its influence on the other aspects in tumor microenvironemt is less discussed. This review elaborates on VEGF's impact on intercellular interactions within the tumor microenvironment, including how VEGF affects pericyte proliferation and migration and mediates interactions between tumor-associated macrophages and cancer cells, resulting in PDL-1-mediated immunosuppression and Nrf2-mediated epithelial-mesenchymal transition. The review discusses VEGF's involvement in intra-organelle crosstalk, tumor metabolism, stemness, and epithelial-mesenchymal transition. It also provides insights into current anti-VEGF therapies and their limitations in cancer treatment. Overall, this review aims to provide a thorough overview of the current state of knowledge concerning VEGF signaling and its impact, not only on angiogenesis but also on various other oncogenic processes.
Keywords: Angiogenesis; Anti-VEGF therapies; Intercellular crosstalk; Intra-organelle crosstalk; Tumor microenvironment; VEGF-VEGFR.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial or personal interests that could have appeared to influence the manuscript.
Similar articles
-
Hypoxia-inducible factor 1alpha and vascular endothelial growth factor in Glioblastoma Multiforme: a systematic review going beyond pathologic implications.Oncol Res. 2024 Jul 17;32(8):1239-1256. doi: 10.32604/or.2024.052130. eCollection 2024. Oncol Res. 2024. PMID: 39055895 Free PMC article.
-
Dll4-Notch signaling in regulation of tumor angiogenesis.J Cancer Res Clin Oncol. 2014 Apr;140(4):525-36. doi: 10.1007/s00432-013-1534-x. Epub 2013 Oct 10. J Cancer Res Clin Oncol. 2014. PMID: 24114288 Free PMC article. Review.
-
Angiogenesis and Resistance Mechanisms in Glioblastoma: Targeting Alternative Vascularization Pathways to Overcome Therapy Resistance.Curr Pharm Des. 2025 Jul 22. doi: 10.2174/0113816128367551250703122830. Online ahead of print. Curr Pharm Des. 2025. PMID: 40698688
-
Active peptides of TSP-1 inhibit retinal angiogenesis through the CD36 pathway in a rat model of choroidal neovascularization.PLoS One. 2025 Jun 20;20(6):e0325661. doi: 10.1371/journal.pone.0325661. eCollection 2025. PLoS One. 2025. PMID: 40540467 Free PMC article.
-
Depressive Disorder Affects TME and Hormonal Changes Promoting Tumour Deterioration Development.Immunology. 2025 Aug;175(4):403-418. doi: 10.1111/imm.13933. Epub 2025 May 8. Immunology. 2025. PMID: 40341563 Review.
Cited by
-
Research progress of ankyrin repeat domain 1 protein: an updated review.Cell Mol Biol Lett. 2024 Oct 17;29(1):131. doi: 10.1186/s11658-024-00647-w. Cell Mol Biol Lett. 2024. PMID: 39420247 Free PMC article. Review.
-
Comparison of Survival Between Different Histological Subtypes in Cervical Cancer Patients: A Retrospective and Propensity Score-matched Analysis.J Cancer. 2024 Oct 14;15(19):6326-6335. doi: 10.7150/jca.100653. eCollection 2024. J Cancer. 2024. PMID: 39513111 Free PMC article.
-
Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs).Front Pharmacol. 2025 Jan 9;15:1463520. doi: 10.3389/fphar.2024.1463520. eCollection 2024. Front Pharmacol. 2025. PMID: 39850566 Free PMC article. Review.
-
Bioinformatic analysis and experimental validation implicate STAT2-mediated angiogenic responses in rosacea pathogenesis.Arch Dermatol Res. 2025 Feb 13;317(1):398. doi: 10.1007/s00403-025-03915-7. Arch Dermatol Res. 2025. PMID: 39945902
-
Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy.Curr Treat Options Oncol. 2025 Mar;26(3):213-225. doi: 10.1007/s11864-025-01306-8. Epub 2025 Mar 6. Curr Treat Options Oncol. 2025. PMID: 40045029 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources